Skip to content

Home Search Authors Pakistan News Saved

SciRah

SciRah does not host or store research papers. Results come live from free, official scholarly APIs, and every paper links back to its original source.

Data sources

OpenAlex
Semantic Scholar
Crossref
CORE
arXiv
PubMed

Privacy policy Terms of service

D. Carlile · SciRah

Researcher profile · Semantic Scholar

D. Carlile

Share profile

D. Carlile — researcher profile on SciRah

h-index: 25
Works: 65
Citations: 3,023

Most-cited papers

Scaling factors for the extrapolation of in vivo metabolic drug clearance from in vitro data: reaching a consensus on values of human microsomal protein and hepatocellularity per gram of liver.
Z. Barter, M. Bayliss, P. Beaune, A. Boobis +8 more
2007Current drug metabolism466 citations
Semantic Scholar
Glofitamab, a Novel, Bivalent CD20-Targeting T-Cell–Engaging Bispecific Antibody, Induces Durable Complete Remissions in Relapsed or Refractory B-Cell Lymphoma: A Phase I Trial
M. Hutchings, F. Morschhauser, G. Iacoboni, C. Carlo-Stella +19 more
2021Journal of Clinical Oncology379 citations Open access
Semantic Scholar
Prediction of hepatic clearance from microsomes, hepatocytes, and liver slices.
J. Houston, D. Carlile
1997Drug metabolism reviews (Softcover ed.)330 citations
Semantic Scholar
Selumetinib Plus Docetaxel Compared With Docetaxel Alone and Progression-Free Survival in Patients With KRAS-Mutant Advanced Non–Small Cell Lung Cancer: The SELECT-1 Randomized Clinical Trial
P. Jänne, M. van den Heuvel, F. Barlesi, M. Cobo +16 more
2017Journal of the American Medical Association (JAMA)323 citations Open access
Semantic Scholar
Phase 1 study results of the type II glycoengineered humanized anti-CD20 monoclonal antibody obinutuzumab (GA101) in B-cell lymphoma patients.
G. Salles, F. Morschhauser, T. Lamy, N. Milpied +8 more
2012Blood202 citations
Semantic Scholar
A phase 1 study of obinutuzumab induction followed by 2 years of maintenance in patients with relapsed CD20-positive B-cell malignancies.
L. Sehn, S. Assouline, D. Stewart, J. Mangel +5 more
2012Blood154 citations Open access
Semantic Scholar
The Use of Tissue Slices for Pharmacotoxicology Studies
P. H. Bach, A. Vickers, R. Fisher, A. Baumann +7 more
199688 citations
Semantic Scholar
Population Pharmacokinetics of Obinutuzumab (GA101) in Chronic Lymphocytic Leukemia (CLL) and Non-Hodgkin's Lymphoma and Exposure–Response in CLL
E. Gibiansky, L. Gibiansky, D. Carlile, C. Jamois +2 more
2014CPT: Pharmacometrics & Systems Pharmacology84 citations Open access
Semantic Scholar
Randomized phase 2 study of obinutuzumab monotherapy in symptomatic, previously untreated chronic lymphocytic leukemia.
J. Byrd, J. Flynn, T. Kipps, M. Boxer +6 more
2016Blood80 citations Open access
Semantic Scholar
Pharmacodynamics and molecular correlates of response to glofitamab in relapsed/refractory non-Hodgkin lymphoma
Ann-Marie E. Bröske, K. Korfi, A. Belousov, Sabine Wilson +12 more
2021Blood Advances78 citations Open access
Semantic Scholar
Prediction of in vivo disposition from in vitro systems: clearance of phenytoin and tolbutamide using rat hepatic microsomal and hepatocyte data.
E. I. L. Ashforth, D. Carlile, R. Chenery, J. Houston
1995Journal of Pharmacology and Experimental Therapeutics67 citations
Semantic Scholar
Glofitamab in Relapsed/Refractory Mantle Cell Lymphoma: Results From a Phase I/II Study
T. Phillips, C. Carlo-Stella, Franck Morschhauser, E. Bachy +14 more
2024Journal of Clinical Oncology56 citations Open access
Semantic Scholar
Microsomal prediction of in vivo clearance and associated interindividual variability of six benzodiazepines in humans
H. Rawden, D. Carlile, A. Tindall, D. Hallifax +3 more
2005Xenobiotica; the fate of foreign compounds in biological systems52 citations
Semantic Scholar
Glofitamab Step-up Dosing Induces High Response Rates in Patients with Hard-to-Treat Refractory or Relapsed Non-Hodgkin Lymphoma
M. Hutchings, C. Carlo-Stella, E. Bachy, F. Offner +13 more
202049 citations Open access
Semantic Scholar
Kinetics of diazepam metabolism in rat hepatic microsomes and hepatocytes and their use in predicting in vivo hepatic clearance.
K. Zomorodi, D. Carlile, J. Houston
1995Xenobiotica; the fate of foreign compounds in biological systems48 citations
Semantic Scholar
Incorporation of in vitro drug metabolism data into physiologically-based pharmacokinetic models.
J. Houston, D. Carlile
1997Toxicology in Vitro40 citations
Semantic Scholar
Rationale for optimal obinutuzumab/GA101 dosing regimen in B-cell non-Hodgkin lymphoma
G. Cartron, F. Hourcade‐Potelleret, F. Morschhauser, G. Salles +3 more
2016Haematologica37 citations Open access
Semantic Scholar
Implications and consequences of enzyme induction on preclinical and clinical drug development
P. Worboys, D. Carlile
2001Xenobiotica; the fate of foreign compounds in biological systems37 citations
Semantic Scholar
Phase I Study of RO5072759 (GA101) in Patients with Relapsed/Refractory CD20+ Non-Hodgkin Lymphoma (NHL).
G. Salles, F. Morschhauser, T. Lamy, N. Milpied +5 more
200935 citations
Semantic Scholar
Glofitamab Monotherapy Induces High Complete Response Rates in Patients with Heavily Pretreated Relapsed or Refractory Mantle Cell Lymphoma
T. Phillips, M. Dickinson, F. Morschhauser, E. Bachy +14 more
2022Blood34 citations
Semantic Scholar
Glofitamab (Glofit) in Combination with Polatuzumab Vedotin (Pola): Phase Ib/II Preliminary Data Support Manageable Safety and Encouraging Efficacy in Relapsed/Refractory (R/R) Diffuse Large B-Cell Lymphoma (DLBCL)
M. Hutchings, A. Sureda, M. Terol, Francesc Bosch Albareda +11 more
2021Blood34 citations Open access
Semantic Scholar
SELECT-2: a phase II, double-blind, randomized, placebo-controlled study to assess the efficacy of selumetinib plus docetaxel as a second-line treatment of patients with advanced or metastatic non-small-cell lung cancer
J. Soria, A. Fülöp, C. Maciel, J. Fischer +15 more
2017Annals of Oncology32 citations Open access
Semantic Scholar
Kinetics of drug metabolism in rat liver slices: IV. Comparison of ethoxycoumarin clearance by liver slices, isolated hepatocytes, and hepatic microsomes from rats pretreated with known modifiers of cytochrome P-450 activity.
D. Carlile, N. Hakooz, J. Houston
1999Drug Metabolism And Disposition31 citations
Semantic Scholar
Impact of acid-reducing agents on gastrointestinal physiology and design of biorelevant dissolution tests to reflect these changes.
Domagoj Segregur, T. Flanagan, J. Mann, Andrea Moir +5 more
2019Journal of Pharmacy and Science30 citations
Semantic Scholar
Glofitamab Step-up Dosing Induces High Response Rates in Patients (pts) with Relapsed or Refractory (R/R) Mantle Cell Lymphoma (MCL), Most of Whom Had Failed Prior Bruton's Tyrosine Kinase Inhibitor (BTKi) Therapy
T. Phillips, M. Dickinson, F. Morschhauser, E. Bachy +12 more
2021Blood29 citations Open access
Semantic Scholar
Selumetinib in combination with docetaxel as second-line treatment for patients with KRAS-mutant advanced NSCLC: results from the phase III SELECT-1 trial.
P. Jänne, M. van den Heuvel, F. Barlesi, M. Cobo +16 more
201623 citations Open access
Semantic Scholar
Evidence of a Drug–Drug Interaction Linked to Inhibition of Ester Hydrolysis by Orlistat
D. Bentley, Anne-Marie Young, L. Rowell, G. Gross +2 more
2012Journal of Cardiovascular Pharmacology22 citations
Semantic Scholar
Population pharmacokinetics of the MEK inhibitor selumetinib and its active N‐desmethyl metabolite: data from 10 phase I trials
P. Patel, E. Howgate, Paul D. Martin, D. Carlile +2 more
2018British Journal of Clinical Pharmacology17 citations Open access
Semantic Scholar
Population Pharmacokinetics of Selumetinib and Its Metabolite N‐desmethyl‐selumetinib in Adult Patients With Advanced Solid Tumors and Children With Low‐Grade Gliomas
Y. Patel, V. Daryani, P. Patel, Diansong Zhou +5 more
2017CPT: Pharmacometrics & Systems Pharmacology17 citations Open access
Semantic Scholar
Challenges and Opportunities for Quantitative Clinical Pharmacology in Cancer Immunotherapy: Something Old, Something New, Something Borrowed, and Something Blue
M. Stroh, D. Carlile, Chi-Chung Li, J. Wagg +9 more
2015CPT: Pharmacometrics & Systems Pharmacology17 citations Open access
Semantic Scholar
Comparative study of the metabolism of drug substrates by human cytochrome P450 3A4 expressed in bacterial, yeast and human lymphoblastoid cells
J. Andrews, M. Abdellah, N. Randolph, K. Kenworthy +3 more
2002Xenobiotica; the fate of foreign compounds in biological systems17 citations
Semantic Scholar
Glofitamab monotherapy in patients with heavily pretreated relapsed/refractory (R/R) mantle cell lymphoma (MCL): Updated analysis from a phase I/II study.
T. Phillips, Carmelo Carlo-Stella, F. Morschhauser, E. Bachy +13 more
2024Journal of Clinical Oncology15 citations Open access
Semantic Scholar
Pharmacokinetics and pharmacogenetics of the MEK1/2 inhibitor, selumetinib, in Asian and Western healthy subjects: a pooled analysis
A. Dymond, C. Elks, Paul D. Martin, D. Carlile +6 more
2017European Journal of Clinical Pharmacology15 citations Open access
Semantic Scholar
Population Pharmacokinetics and Exposure-Response Analyses for Glofitamab in Relapsed/Refractory B-Cell Non-Hodgkin Lymphoma (R/R NHL): Confirmation of Efficacy and CRS Mitigation in Patients with Step-up Dosing
Nassim Djebli, P. N. Morcos, Félix Jaminion, E. Guerini +7 more
2020Blood14 citations Open access
Semantic Scholar
Results from the first-in-human (FIH) phase I study of RO5520985 (RG7221), a novel bispecific human anti-ANG-2/anti-VEGF-A antibody, administered as an intravenous infusion to patients with advanced solid tumors.
M. Hidalgo, C. le Tourneau, C. Massard, V. Boni +15 more
201412 citations
Semantic Scholar
Effect of Hepatic and Renal Impairment on the Pharmacokinetics of Dalcetrapib
M. Phelan, J. Anzures‐Cabrera, D. Carlile, L. Rowell +4 more
2013Clinical Pharmacokinetics10 citations
Semantic Scholar
Phase 1 Study of CD19 Targeted CD28 Costimulatory Agonist in Combination with Glofitamab to Enhance T Cell Effector Function in Relapsed/Refractory B Cell Lymphoma
M. Dickinson, G. Gritti, C. Carlo-Stella, H. Walter +18 more
2022Blood6 citations Open access
Semantic Scholar
Development of a Predictive Model for Cytokine Release Syndrome to Inform Risk Stratification and CRS Management Following Immunotherapy
K. Komanduri, A. Belousov, M. Byrtek, A. Kwan +6 more
2021Blood6 citations Open access
Semantic Scholar
Population Pharmacokinetic and Exposure‐Response Analysis of Selumetinib and Its N‐desmethyl Metabolite in Patients With Non‐Small Cell Lung Cancer
Xiao Tong, Hongmei Xu, D. Carlile, H. Tomkinson +2 more
2018Journal of clinical pharmacology6 citations
Semantic Scholar
Pharmacokinetics of RO5072759 (GA101) In Patients with Relapsed/Refractory CD20+ Malignant Disease (Phase I/II Study BO20999)
G. Meneses-Lorente, D. Carlile, J. Birkett, M. Wenger +3 more
20106 citations
Semantic Scholar
Glofitamab step-up dosing (SUD): Complete response rates in updated efficacy data in heavily pretreated relapsed/refractory (R/R) non-Hodgkin lymphoma (NHL) patients (pts).
C. Carlo-Stella, M. Hutchings, F. Offner, F. Morschhauser +14 more
20215 citations
Semantic Scholar
Pharmacokinetics of Obinutuzumab (GA101) in Patients with CD20+ Relapsed/Refractory Malignant Disease Receiving Concomitant Chemotherapy (Phase Ib Study BO21000),
D. Carlile, G. Meneses-Lorente, Elisabeth Wassner-Fritsch, F. Hourcade‐Potelleret +6 more
20115 citations
Semantic Scholar
GLOFITAMAB STEP‐UP DOSING: UPDATED EFFICACY DATA SHOW HIGH COMPLETE RESPONSE RATES IN HEAVILY PRETREATED RELAPSED/REFRACTORY (R/R) NON‐HODGKIN LYMPHOMA (NHL) PATIENTS
C. Carlo-Stella, M. Hutchings, F. Offner, F. Morschhauser +14 more
2021Hematological Oncology3 citations Open access
Semantic Scholar
Interaction potential of Carmegliptin with P-glycoprotein (Pgp) transporter in healthy volunteers
O. Kuhlmann, D. Carlile, J. Noé, D. Bentley
2014Journal of Drug Assessment3 citations Open access
Semantic Scholar
New Tocilizumab (TCZ) Dosing Guidance for T-Cell Engaging Bispecific Antibody-Related Cytokine Release Syndrome (CRS) in Patients (pts) with Relapsed/Refractory (R/R) B-Cell Non-Hodgkin Lymphoma (B-NHL): Insights from Pooled Clinical Trial Safety Experience and Quantitative Clinical Pharmacology (qC
C. Jamois, David C. Turner, Leonid Gibiansky, Feifei Li +10 more
2023Blood2 citations
Semantic Scholar
Poster:ABCL-360 Glofitamab Step-Up Dosing (SUD): Updated Efficacy Data Show High Complete Response Rates in Heavily Pretreated Relapsed/Refractory (R/R) Non-Hodgkin Lymphoma (NHL) Patients (Pts)
C. Carlo-Stella, C. Khan, M. Hutchings, F. Offner +15 more
20212 citations
Semantic Scholar
Recovery of major human CYP isoforms during microsomal preparation. Implications for in vitro-in vivo scaling. At 12th International Symposium on Microsomes and Drug Oxidations, Montpellier, France
D. Carlile, B. Houston
19982 citations
Semantic Scholar
Prediction of intrinsic clearance of CYP2C9 substrates in man using hepatic microsomes: imortance of Km.
D. Carlile, M. Bayliss, B. Houston
19982 citations
Semantic Scholar
Oral Abstract: ABCL-360: Glofitamab Step-Up Dosing (SUD): Updated Efficacy Data Show High Complete Response Rates in Heavily Pretreated Relapsed/Refractory (R/R) Non-Hodgkin Lymphoma (NHL) Patients (Pts)
C. Carlo-Stella, C. Khan, M. Hutchings, F. Offner +15 more
20211 citations
Semantic Scholar
Abstract 4760: Joint modeling of longitudinal tumor dynamics and survival in non-small cell lung cancer (NSCLC) patients
Xiao Tong, J. Dunyak, Dian-Song Zhou, D. Carlile +4 more
2018Regulatory Science and Policy1 citations
Semantic Scholar

Frequent co-authors

Invite them to SciRah by sharing their profile.

F. Morschhauser×15
Invite
F. Morschhauser — researcher profile on SciRah
L. Lundberg×12
Invite
L. Lundberg — researcher profile on SciRah
M. Dickinson×11
Invite
M. Dickinson — researcher profile on SciRah
J. Relf×10
Invite
J. Relf — researcher profile on SciRah

C. Carlo-Stella

×9

Invite

C. Carlo-Stella — researcher profile on SciRah

Invite

F. Offner — researcher profile on SciRah

Invite

M. Crump — researcher profile on SciRah

Invite

K. Humphrey — researcher profile on SciRah

Invite

J. Houston — researcher profile on SciRah

M. Hutchings×8

Invite

M. Hutchings — researcher profile on SciRah

Invite

A. Belousov — researcher profile on SciRah

D. Pérez-Callejo×7

Invite

D. Pérez-Callejo — researcher profile on SciRah